Key Trends in Offshoring Pharmaceutical R&D: Company strategies, emerging markets and impact on ROI–Aarkstore Enterprise

Posted January 11, 2010 by Editor in Future Trends | No comments yet

Aarkstore announce a new report  “Key Trends in Offshoring Pharmaceutical R&D: Company strategies, emerging markets and impact on ROI” through its vast collection of market research report.

Key Trends in Offshoring Pharmaceutical R&D: Company strategies, emerging markets and impact on ROIs

Offshoring and outsourcing have become an increasingly critical contributor to pharma and biotech R&D strategies in recent years. They enable companies to focus on core competencies such as drug discovery or technology development whilst contracting out non-core processes to experts, often at lower costs. As offshore investments begin to mature and provide returns on investment, the opportunity to migrate individual components or whole segments of R&D portfolios will continue to rise.

‘Key Trends in Offshoring Pharmaceutical R&D’ is a report published evaluates the offshore R&D strategies that can reduce development times and improve productivity, with analysis of a variety of strategic partnerships, academic collaborations, and outsourcing opportunities. This report identifies emerging areas of technological and scientific significance across the globe and examines the offshore strategies and investments of the top 20 pharma and biotech companies across Asia, Australia, Central and Eastern Europe, Latin America and the Far East. This report also provides a financial and managerial valuation of leading companies based on their P/E ratio, return on assets (ROA) and return on investment (ROI) and measures company performance against the healthcare industry, pharmaceutical and biotechnology sectors and leading shares of the S&P500.

Key Findings

Companies that have allocated over 60% of their R&D expenditure offshore have displayed greater shareholder return, operating margins, market capital growth and return on assets.

The US currently attracts 53% of total industry R&D spend, however it is forecast that 20% of this expenditure will migrate to Asia Pacific by 2010. Australia, China and Singapore are emerging as key areas for scientific and technological investment.

Leading pharma and biotech companies have undergone major R&D restructuring over the last five years and now adopt a focused, streamlined global approach which is increasingly reliant on offshore strategic partnerships, academic collaboration and outsourcing to establish networks of scientific expertise.

Scientific and technological excellence within emerging economies is a key incentive for offshore investment, enabling companies to enhance innovation and productivity within their R&D programs.

Managerial expertise is a critical factor driving the success of offshore investments, helping leading pharma and healthcare companies to outperform their peers and the S&P 500 index in 2008.

Use this report to…

Assess the offshore R&D strategies of the top 20 pharma and biotech companies with this report’s analysis of offshore investment and deal trends over the last five years.

Discover which geographic regions have the greatest potential for offshore R&D investment by identifying key areas of technological, scientific and academic expertise across Asia Pacific, Australia, Eastern Europe, Latin America, the Middle East and South Africa.

Measure how the offshore strategies of the top 20 pharma and biotech companies have influenced their R&D productivity and efficiency with this report’s financial and managerial performance review, comparative analysis of healthcare/pharma/biotech sectors and S&P500 index assessment.

Identify the key drivers and opportunities for offshore investment with this report’s analysis of major offshoring trends and R&D developments.

Explore issues including…

Shifting focus of R&D strategies. The industry has become more globalized in its R&D approach as part of efforts to improve productivity and efficiency. Networks of offshore partnerships and academic collaborations are now enabling companies to harness external expertise on a project by project basis.

Offshore investment in emerging economies. Companies are increasingly turning to emerging countries to counter the slowing growth of US and European markets. Investing in offshore R&D facilities provides companies with local expertise and a greater understanding of local economies.

Offshore opportunities in tertiary economies. The success of commercial opportunities in emerging markets has expanded the regional scope of investment, with Australia, Israel and Singapore all seen to provide labour arbitrage and access to specialists.

Focused managerial directives are critical. Successful R&D performance is underpinned by a streamlined R&D strategy which is well managed by a team of scientists, technologists and non-scientists which can guide global networks ensuring early go/no go decision making which builds on the core competencies of both internal and external researchers.

Discover…

Which countries are attracting offshore investment?

Which areas of research and technology are attracting offshore investment?

How are the leading pharma and biotech companies changing their R&D programs?

Which major companies and academic institutions have attracted offshore investment?

What factors are driving offshore investment?

What is the financial performance of the leading pharma and biotech companies based on P/E ratio compared to their peers and the S&P500?

Which companies have delivered the best return on assets and return on investment during the last five years?

How will offshore investment influence R&D productivity in the future?

For more information, please visit :
http://www.aarkstore.com/reports/Key-Trends-in-Offshoring-Pharmaceutical-R-D-Company-strategies-emerging-markets-and-impact-on-ROI-13950.html
Or email us at press@aarkstore.com or call +919272852585

Special offer till 31th Dec 2009

Article By:

The Evolving Pharma M&A Landscape: Emerging trends and predicted post-blockbuster targets–Aarkstore Enterprise

Posted January 9, 2010 by Editor in Future Trends | No comments yet

Aarkstore announce a new report  ” The Evolving Pharma M&A Landscape: Emerging trends and predicted post-blockbuster targets ” through its vast collection of market research report.

Pharmaceutical market growth rates have halved inside the past five years, and will remain modest into the next decade. At the same time, new drug approval rates have slowed. With costs continuing to rise, the industry’s margins are already being squeezed, but will come under growing pressure as payers adopt more stringent pharmaceutical cost-containment policies and as patents on a slew of blockbusting brands expire.

Multinationals are scrambling to adjust to this new, more austere market environment. All of the sector’s leading players are pursuing major cost-cutting programs, but these alone will not be sufficient to paper over cracks in the traditional big pharma model. More radical restructuring – often through merger or acquisition deals – will be required to solve the industry’s underlying problems.

Pfizer and Merck have each announced mega-mergers designed to breathe new life into their respective businesses. Few of the global-scale deals concluded since the mid-1990s have delivered major long-term benefits, however, and a growing number of big pharma CEOs have begun to pursue more nuanced M&A strategies. Key trends include the pursuit of biotech/ biopharma targets to bolster multinational pipelines; expansion into developing countries; the establishment of a presence in the generics sector; and the purchase of assets in lower-risk segments of the healthcare market.

The world’s ten biggest pharmaceutical companies have committed almost $230bn to M&A deals since the beginning of 2007. The size of their assets and the cash-generating capabilities of their existing businesses have rendered them largely immune from the effects of the global economic downturn, during which big pharma M&A spending has actually accelerated. Key M&A announcements will continue to be made on a regular basis into 2010 and beyond.

Key issues addressed in this report

Pharmaceutical industry pressure points: Pharmaceutical industry revenues and margins will come under growing pressure as payers impose more stringent cost-containment policies, and as patent expiries erode sales generated by existing major brands.

M&A drivers: Multinational M&A activity will be driven by efforts to bolster pipelines, expand businesses beyond traditional core geographic boundaries, cash in on the generics boom and broaden the scope of existing activities.

M&A funding capabilities: Big pharma’s huge financial assets and the cash-generating capabilities of multinational prescription drug businesses will allow companies to continue accessing funds to support M&A investment at substantial levels.

Mega-mergers: While history shows that few mega-mergers have delivered real long-term benefits for buyers or their shareholders, the ‘quick fix’ that such transactions offer is clearly still difficult for some to resist. The deals unveiled by Pfizer and Merck in 2009 will not be the last global-scale transactions witnessed in the sector, but a more strategic approach to M&A activity will begin to prevail.

The rush into biotech: Multinationals will continue to raise their stakes in the biotech industry as they attempt to shore up in-house pipelines. Competition for the most attractive biotech targets is increasingly fierce, however, and buyers will be forced to pay substantial premiums in order to secure quality biotech assets.

Cashing in on the generics boom: More multinationals will invest in the acquisition of generic businesses. Targets will include global commodity-type manufacturers, emerging biosimilar specialists and national or regional producers of the branded generics that dominate drug sales in many developing markets.

Key findings of this report

The pharmaceutical industry’s ten biggest players face the expiry of patents on brands that generate annual revenues of more than $130bn within the next five years. This ‘patent cliff’ is driving the acquisition of biotech assets designed to strengthen big pharma pipelines.

Biotech/biopharma companies were the subject of nearly half the M&A transactions completed or announced by leading pharmaceutical companies between January 2007 and July 2009, and accounted for four of the ten biggest M&A deals witnessed in that period.

The world’s ten biggest pharmaceutical companies generated prescription drug sales totaling $308bn in 2008. Their operations generated aggregate net cash of more than $106bn and pre-tax profits of $81bn. At the end of 2008 they were sitting on collective net assets worth $354bn.

The ten leading companies have completed or reached definitive agreements on 64 M&A deals since January 2007. Together, they have committed almost $230bn to healthcare M&A transactions in the past two-and-a-half years.

Biotech companies aside, consumer healthcare and generic businesses are among the most popular acquisition targets, reflecting a desire on the part of big pharma to reduce levels of exposure to conditions in the global market for prescription drugs.

Two of the world’s five biggest generics businesses are active candidates for disposal. Sandoz and Teva aside, all of the world’s other leading generic companies are potential acquisition targets.

This report provides

Analysis of key pressure points affecting the global pharmaceutical industry and of the sector’s efforts to adjust to these unprecedented challenges.

Comparative analysis of leading pharmaceutical finances, development pipelines and exposure to major patent expiries.

Comprehensive tracking of individual company M&A activity since January 2007.

Insights into individual company M&A strategies and the likely nature of future M&A activity.

Critical appraisal of previous pharmaceutical mega-mergers, and of the pending Pfizer/Wyeth and Merck/Schering-Plough transactions.

Analysis of conditions in the global biotech and generics markets, factors driving consolidation and identification fo key M&A targets in each of these two sectors.

Use this report to:

Quantify individual pharmaceutical company exposure to major patent expiries in the next five years.

Compare the strengths and weaknesses of big pharma pipelines and identify the gaps that biotech acquisitions will be used to plug.

Track recent M&A activity by the world’s ten biggest pharmaceutical companies in terms of both deal values and strategic intent.

Gain valuable insights into the strategic approaches to M&A activity being pursued by individual big pharma CEOs.

Understand why most previous pharmaceutical mega-mergers failed to deliver long-term benefits, and how Pfizer and Merck hope to avoid repeating the industry’s past mistakes.

Identify prime biotech/biopharma acquisition targets and the global, regional or national generic businesses most likely to attract acquisition bids.

For more information, please visit :
http://www.aarkstore.com/reports/The-Evolving-Pharma-M-A-Landscape-Emerging-trends-and-predicted-post-blockbuster-targets-34831.html
Or email us at press@aarkstore.com or call +919272852585

Special offer till 31th Dec 2009

Article By:

Emerging Biotech Sector in Malaysia

Posted January 4, 2010 by Editor in Future Trends | No comments yet

Emerging Biotech Sector in Malaysia

Malaysia has emerged as a major investment destination for biotech companies. The Malaysian biotech market posted high growth last year and is expected to do the same in next few years. Rich biodiversity, availability of low cost human resources and strong government efforts are some of the reasons that have boosted growth in the market. According to our new research report “Emerging Biotech Sector in Malaysia”, the biotech market in Malaysia is expected to grow at a CAGR of around 21% during 2010-2012. ( http://www.bharatbook.com/detail.asp?id=126896&rt=Emerging-Biotech-Sector-in-Malaysia.html )

We have studied the Malaysian biotech market by breaking it into three segments – healthcare biotech, agriculture biotech and industrial biotech. Each of these segments has been extensively covered in the report, giving in-depth analysis of the current and future market trends along with valuable data of past trends. Our report also provides a complete overview of regulatory environment for the biotech market.

Our report has found that increasing prevalence of diseases and rising exports of drugs from Malaysia are driving growth in the healthcare biotechnology market. This segment holds the highest potential for growth and will post the fastest growth rate among all the three segments. Besides, the country’s expertise in agriculture sector will give strong impetus to the growth of this segment in near future whereas surging exports of biofuels and palm oil will boost the industrial biotech segment. Moreover, our report also provides a complete overview of restraints that are blocking growth in the industry coupled with certain useful recommendations, which will be useful for both government and clients in future prospects.

The report studies the current development process and its effects on various segments of the industry. The research study gives detailed statistical and analytical information of macroeconomic indicators, key drivers and restraints. It also contains brief overview of government initiatives and key industry players that will help clients to draw up market strategies and assess areas of opportunity in the Malaysian biotech market.
 

To know more and to buy a copy of your report feel free to visit : http://www.bharatbook.com/detail.asp?id=126896&rt=Emerging-Biotech-Sector-in-Malaysia.html

Or

Contact us at :

Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com
Blog: http://bharatbookresearch.blogspot.com
Follow us on twitter: http://twitter.com/3bbharatbook

Article By: